This profile was last updated on .
Is this you? Claim your profile.
1620 W Fountainhead Pwky Ste 501
Incorporated in 1985 as SNAP Systems, SL-Tech is solely focused on K-12 school foodservice business solutions. SL-Tech, owned by Lawrence Goodman III, is the school foodservice industry's recognized leader. SL-Tech has always been first to market with the...
Find other employees at this company (34)
(95 Total References)
A naturally-occurring soy peptide, ...
A naturally-occurring soy peptide, discovered by UC Berkely scientist Dr. Alfredo Galvez in 1996 as a result of his research to improve the nutritional profile of soy protein.
Further research by Alfredo F. Galvez sought to prove that lunasin is the active agent in soy responsible for these benefits.
produced a lunasin extract that is 100-200 times more potent than typical a soy isolate.
Dr. Galvez's research
proved lunasin to be responsible for the LDL cholesterol lowering benefit associated with soy.
Dr. Alfredo Galvez
Chief Scientific Officer at SL Tech, a Reliv Company
Interestingly, pointed out Dr. ...
Interestingly, pointed out Dr. Alfredo Galvez, chief scientific advisor at Missouri-based SL Technology (a Reliv company), a majority of the mass marketing for cholesterol management is from pharmaceutical companies, therefore many individuals associate cholesterollowering treatments with prescription medicines over dietary supplements.
"The most compelling result of recent clinical trials on cholesterol management is that the only significant causal association between cholesterol lowering and reducing risk for CVD is by treatment with statin drugs," explained Galvez
LunaRich products, said Galvez
, "are the only nutritional products on the market that have a similar mechanism of action to that of statin drugs.
Progress In The Cholesterol Puzzle - Nutrition Industry Executive Magazine
According to Dr. Alfredo Galvez, lead scientific advisor with Missouri-based Soy Labs, LLC, some of the "megatrends" that are driving the nutrition market in general are directly impacting this category."An aging population, lack of confidence in traditional health care systems and globalization/consumer access to information are compelling shoppers to be proactive and seek alternative solutions to their health concerns," he said.
"Most cholesterol is produced in the liver by the HMG-CoA reductase gene.Statin drugs work by blocking HMGCoA, but they can often block too much," Galvez
"This leads to serious side effects because our body needs a minimum level of cholesterol for proper cellular functions such as maintaining cell membrane integrity and hormone production.
According to Galvez
, lunasin works differently: it targets cholesterol at an earlier stage than statins, reducing the HMG-CoA without blocking it entirely.
"Lunasin demonstrates superior support for cardiovascular health and exhibits significant anti-inflammatory properties," he
Compared to statins, lunasin works at an earlier stage in the process than prescription statins by reducing the expression of the HMG-CoA Reductase gene, according to Galvez
"While cholesterol is an accepted biomarker for identifying the risk factors associated with cardiovascular disease, other potential biomarkers (e.g. inflammation markers, circulating free fatty acids, etc.) are being identified that may play and equally important role in heart health," Galvez
"The key to future innovations in this segment will be finding bioactive compounds that work synergistically to support heart health by addressing the many inter-related health indicators."
Further, a new take on statins may be forthcoming.
"Recently research is considering the use of low-dose statin treatment for primary prevention of cardiovascular disease," Galvez
Lunasin & Epigentics | Janet Summerfelt
Dr. Alfredo Galvez narrates the second half of the video to explain how lunasin works at the epigenetic level to promote optimal health.
"It means you have more control over your health than you think you do," said Dr. Alfredo Galvez, research scientist at the Center of Excellence in Nutritional Genomics at UC Davis and lead scientific advisor at the Missouri Plant Science Center.
"I believe epigenetics holds the key to the future of health care," Galvez
1996: Lunasin discovered by Dr. Alfredo Galvez at UC Berkeley
approves heart health claim for soy protein
2008: Dr. Galvez
presents lunasin's epigenetic mechanism of action for lowering cholesterol
2012: Dr Galvez
presents the lunasin research in front of the American Heart Association's